Guidelines on the management of AL amyloidosis

British Journal of Haematology

Volumn 168, Issue 2, 2015, Pages 186-206

  Wechalekar, Ashutosh D ^a   Gillmore, Julian D ^a   Bird, Jenny ^b   Cavenagh, Jamie ^c   Hawkins, Stephen ^d   Kazmi, Majid ^e   Lachmann, Helen J ^a   Hawkins, Philip N ^a   Pratt, Guy ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

AL amyloidosis; Amyloid; Chemotherapy; Guidelines; Transplantation

Indexed keywords

AMYLOID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN; MELPHALAN; POMALIDOMIDE; PREDNISOLONE; SERUM AMYLOID P; THALIDOMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CYTOPENIA; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART GRAFT; HEART INJURY; HUMAN; INFECTION; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NEPHROTIC SYNDROME; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PATIENT CARE; PATIENT INFORMATION; PLASMA CELL DYSCRASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

AMYLOIDOSIS; HUMANS;

EID: 84923842057     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13155     Document Type: Article

References (123)

1. Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W. & Moreau, P. (2012) Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica, 97, 1925-1928.
2. Benson, M.D. (1986) Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis and Rheumatism, 29, 683-687.
3. Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., Hutchinson, W.L., Mangione, P.P., Gallimore, J.R., Millar, D.J., Minogue, S., Dhillon, A.P., Taylor, G.W., Bradwell, A.R., Petrie, A., Gillmore, J.D., Bellotti, V., Botto, M., Hawkins, P.N. & Pepys, M.B. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468, 93-97.
4. Bradstock, K., Clancy, R., Uther, J., Basten, A. & Richards, J. (1978) The successful treatment of primary amyloidosis with intermittent chemotherapy. Australian and New Zealand Journal of Medicine, 8, 176-179.
5. Camoriano, J.K., Greipp, P.R., Bayer, G.K. & Bowie, E.J. (1987) Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. New England Journal of Medicine, 316, 1133-1135.
6. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118, 4346-4352.
7. Cohen, A.S., Rubinow, A., Anderson, J.J., Skinner, M., Mason, J.H., Libbey, C. & Kayne, H. (1987) Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). American Journal of Medicine, 82, 1182-1190.
8. Cohen, A.D., Zhou, P., Chou, J., Teruya-Feldstein, J., Reich, L., Hassoun, H., Levine, B., Filippa, D.A., Riedel, E., Kewalramani, T., Stubblefield, M.D., Fleisher, M., Nimer, S. & Comenzo, R.L. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology, 139, 224-233.
9. Comenzo, R.L. & Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 4276-4282.
10. Comenzo, R.L., Vosburgh, E., Falk, R.H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L.M., Berk, J.L., Akpek, G., LaValley, M., O'Hara, C., Arkin, C.F., Wright, D.G. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 3662-3670.
11. Comenzo, R.L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V., Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., Zonder, J., Dispenzieri, A., Gertz, M., Streicher, H., Skinner, M., Kyle, R.A. & Merlini, G. (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia, 26, 2317-2325.
12. Dhodapkar, M.V., Hussein, M.A., Rasmussen, E., Solomon, A., Larson, R.A., Crowley, J.J. & Barlogie, B. (2004) Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 104, 3520-3526.
13. Dietrich, S., Schonland, S.O., Benner, A., Bochtler, T., Kristen, A.V., Beimler, J., Hund, E., Zorn, M., Goldschmidt, H., Ho, A.D. & Hegenbart, U. (2010) Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 116, 522-528.
14. Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S.L. & Liedtke, M. (2013a) Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98, 1593-1599.
15. Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T.I., Schrier, S.L. & Liedtke, M. (2013b) The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. British Journal of Haematology, 161, 367-372.
16. Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Journal of Clinical Oncology, 19, 3350-3356.
17. Dispenzieri, A., Lacy, M.Q., Rajkumar, S.V., Geyer, S.M., Witzig, T.E., Fonseca, R., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 10, 257-261.
18. Dispenzieri, A., Lacy, M.Q., Geyer, S.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Rajkumar, S.V., Kyle, R.A., Fonseca, R. & Gertz, M.A. (2004) Low dose single agent thalidomide is tolerated in patients with primary systemic amyloidosis, but responses are limited. Blood (ASH Annual Meeting Abstracts), 104, 4920.
19. Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. & Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 3378-3383.
20. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465-470.
21. Dispenzieri, A., Zhang, L., Katzmann, J.A., Snyder, M., Blood, E., Degoey, R., Henderson, K., Kyle, R.A., Oken, M.M., Bradwell, A.R. & Greipp, P.R. (2008) Appraisal of immunoglobulin free light chain as a marker of response. Blood, 111, 4908-4915.
22. Dispenzieri, A., Buadi, F., Laumann, K., LaPlant, B., Hayman, S.R., Kumar, S.K., Dingli, D., Zeldenrust, S.R., Mikhael, J.R., Hall, R., Rajkumar, S.V., Reeder, C., Fonseca, R., Bergsagel, P.L., Stewart, A.K., Roy, V., Witzig, T.E., Lust, J.A., Russell, S.J., Gertz, M.A. & Lacy, M.Q. (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 119, 5397-5404.
23. Dubrey, S.W., Burke, M.M., Khaghani, A., Hawkins, P.N., Yacoub, M.H. & Banner, N.R. (2001) Long term results of heart transplantation in patients with amyloid heart disease. Heart, 85, 202-207.
24. Dubrey, S.W., Burke, M.M., Hawkins, P.N. & Banner, N.R. (2004) Cardiac transplantation for amyloid heart disease: the United Kingdom experience. Journal of Heart and Lung Transplantation, 23, 1142-1153.
25. Falk, R.H. (2005) Diagnosis and management of the cardiac amyloidoses. Circulation, 112, 2047-2060.
26. Gertz, M.A. & Merlini, G. (2010) Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid, 17, 48-49.
27. Gertz, M.A., Falk, R.H., Skinner, M., Cohen, A.S. & Kyle, R.A. (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. American Journal of Cardiology, 55(13 Pt 1), 1645.
28. Gertz, M.A., Kyle, R.A. & O'Fallon, W.M. (1992) Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Archives of Internal Medicine, 152, 2245-2250.
29. Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999a) Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. American Journal of Hematology, 61, 115-119.
30. Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999b) Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Medical Oncology, 16, 104-109.
31. Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999c) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. Journal of Clinical Oncology, 17, 262-267.
32. Gertz, M.A., Lacy, M.Q., Gastineau, D.A., Inwards, D.J., Chen, M.G., Tefferi, A., Kyle, R.A. & Litzow, M.R. (2000) Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 26, 963-969.
33. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Ansell, S.M., Elliott, M.A., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Porrata, L.F., Tefferi, A. & Litzow, M.R. (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 34, 1025-1031.
34. Gertz, M.A., Lacy, M.Q., Dispenzieri, A. & Hayman, S.R. (2005a) Amyloidosis. Best Practice and Research. Clinical Haematology, 18, 709-727.
35. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005b) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319-328.
36. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S.K., Dingli, D., Ansell, S.M., Gastineau, D.A., Inwards, D.J., Johnston, P.B., Litzow, M.R., Micallef, I.N., Porrata, L.F., Leung, N., Hogan, W.J. & Buadi, F.K. (2010) Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukaemia & Lymphoma, 51, 2181-2187.
37. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Kumar, S.K., Dingli, D., Leung, N., Hogan, W.J., Buadi, F.K. & Hayman, S.R. (2013) Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 48, 557-561.
38. Gibbs, S.D.J., Venner, C.P., Foard, D., Rannigan, L., Pinney, J.H., Lane, T., Roussel, M., Banypersad, S., Whelan, C.J., Dungo, J., Lachmann, H.J., Gillmore, J.D., Wechalekar, A.D. & Hawkins, P.N. (2012) Subcutaneous bortezomib is effective and well tolerated for the treatment of systemic AL amyloidosis. XIIIth International Symposium on Amyloidosis: From Misfolded Proteins to Well-designed Treatment, PC 40. International Society of Amyloidosis, Rochester, MA.
39. Gillmore, J.D., Davies, J., Iqbal, A., Madhoo, S., Russell, N.H. & Hawkins, P.N. (1998) Allogeneic bone marrow transplantation for systemic AL amyloidosis. British Journal of Haematology, 100, 226-228.
40. Gillmore, J.D., Apperley, J.F., Craddock, C., Madhoo, S., Pepys, M.B. & Hawkins, P.N. (1999) High-dose melphalan and stem cell rescue for AL amyloidosis. In: Amyloid and Amyloidosis 1998 (eds by R.A. Kyle & M.A. Gertz ), pp. 102-104. Parthenon Publishing, Pearl River, NY.
41. Gillmore, J.D., Goodman, H.J., Lachmann, H.J., Offer, M., Wechalekar, A.D., Joshi, J., Pepys, M.B. & Hawkins, P.N. (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107, 1227-1229.
42. Gillmore, J.D., Cocks, K., Gibbs, S.D.J., Sattianayagam, P.T., Lane, T., Lachmann, H.J., Schey, S., Cavenagh, J., Oakervee, H., Morgan, G., Bourne, S., Skinner, E., Bell, S., Booth, G., Foard, D.M., Mehta, A., Hawkins, P.N. & Wechalekar, A.D. (2010a) UK AL amyloidosis Treatment Trial (UKATT) - a randomized study: lessons for future trial design. Amyloid, 17, 88-89.
43. Gillmore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J., Offer, M., Millar, D.J., Petrie, A., Hawkins, P.N. & Pepys, M.B. (2010b) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 148, 760-767.
44. Gillmore, J.D., Wechalekar, A., Bird, J., Cavenagh, J., Hawkins, S., Kazmi, M., Lachmann, H.J., Hawkins, P.N. & Pratt, G. (2014) Guidelines on the diagnosis and investigation of AL amyloidosis. British Journal of Haematology, doi: 10.1111/bjh.13156.
45. Gono, T., Matsuda, M., Shimojima, Y., Ishii, W., Koyama, J., Sakashita, K., Koike, K., Hoshii, Y. & Ikeda, S. (2004) VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid, 11, 245-256.
46. Goodman, H.J.B., Lachmann, H.J. & Hawkins, P.N. (2004) Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis. Blood (ASH Annual Meeting Abstracts), 104, 755A.
47. Goodman, H.J.B., Wechalekar, A.D., Lachmann, H.J., Bradwell, A.R. & Hawkins, P.N. (2005) Survival and responses in 229 patients with AL amyloidosis treated with VAD or VAD-like chemotherapy. Haematologica, 90(Suppl. 1), 201 [abstract].
48. Goodman, H.J., Gillmore, J.D., Lachmann, H.J., Wechalekar, A.D., Bradwell, A.R. & Hawkins, P.N. (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134, 417-425.
49. Greipp, P.R., Kyle, R.A. & Bowie, E.J. (1979) Factor X deficiency in primary amyloidosis: resolution after splenectomy. New England Journal of Medicine, 301, 1050-1051.
50. Hartmann, A., Holdaas, H., Fauchald, P., Nordal, K.P., Berg, K.J., Talseth, T., Leivestad, T., Brekke, I.B. & Flatmark, A. (1992) Fifteen years' experience with renal transplantation in systemic amyloidosis. Transplant International, 5, 15-18.
51. Hawkins, P.N. (1994) Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clinical Science, 87, 289-295.
52. Hayman, S.R., Lacy, M.Q., Kyle, R.A. & Gertz, M.A. (2001) Primary systemic amyloidosis: a cause of malabsorption syndrome. American Journal of Medicine, 111, 535-540.
53. Hosenpud, J.D., DeMarco, T., Frazier, O.H., Griffith, B.P., Uretsky, B.F., Menkis, A.H., O'Connell, J.B., Olivari, M.-T. & Valantine, H.A. (1991) Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Circulation, 84, 338-343.
54. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J.C., Ronco, P., Quet, F., Cogne, M. & Fermand, J.P. (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 357, 1083-1093.
55. Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 1351-1358.
56. Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., Gillmore, J.D. & Palladini, G. (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of Clinical Oncology, 28, 1031-1037.
57. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (Rdc) in AL amyloidosis. Blood, 119, 5384-5390.
58. Kourelis, T.V., Kumar, S.K., Gertz, M.A., Lacy, M.Q., Buadi, F.K., Hayman, S.R., Zeldenrust, S., Leung, N., Kyle, R.A., Russell, S., Dingli, D., Lust, J.A., Lin, Y., Kapoor, P., Rajkumar, S.V., McCurdy, A. & Dispenzieri, A. (2013) Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Journal of Clinical Oncology, 31, 4319-4324.
59. Kristen, A.V., Dengler, T.J., Hegenbart, U., Schonland, S.O., Goldschmidt, H., Sack, F.U., Voss, F., Becker, R., Katus, H.A. & Bauer, A. (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm, 5, 235-240.
60. Kumar, S., Dispenzieri, A., Katzmann, J.A., Larson, D.R., Colby, C.L., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Leung, N., Zeldenrust, S.R., Ramirez-Alvarado, M., Clark, R.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2010) Serum immunoglobulin free light chain measurement in AL amyloidosis: prognostic value and correlations with clinical features. Blood, 116, 5126-5129.
61. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., Allred, J., Laumann, K.M., Bergsagel, L.P., Dingli, D., Mikhael, J.R., Reeder, C.B., Stewart, A.K., Zeldenrust, S.R., Greipp, P.R., Lust, J.A., Fonseca, R., Russell, S.J., Rajkumar, S.V. & Dispenzieri, A. (2012) Lenalidomide, cyclophosphamide, and dexamethasone (Crd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 119, 4860-4867.
62. Kyle, R.A., Wagoner, R.D. & Holley, K.E. (1982) Primary systemic amyloidosis. Resolution of the nephrotic syndrome with melphalan and prednisolone. Archives of Internal Medicine, 142, 1445-1447.
63. Kyle, R.A., Greipp, P.R., Garton, J.P. & Gertz, M.A. (1985) Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. American Journal of Medicine, 79, 708-716.
64. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A. & Lacy, M.Q. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 1202-1207.
65. Lamm, W., Willenbacher, W., Lang, A., Zojer, N., Muldur, E., Ludwig, H., Schauer-Stalzer, B., Zielinski, C.C. & Drach, J. (2011) Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Annals of Hematology, 90, 201-206.
66. Landau, H., Hassoun, H., Rosenzweig, M.A., Maurer, M., Liu, J., Flombaum, C., Bello, C., Hoover, E., Riedel, E., Giralt, S. & Comenzo, R.L. (2013) Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia, 27, 823-828.
67. Lane, T., Foard, D.M., Wechalekar, A.D., Gibbs, S.D.J., Lachmann, H.J., Sattianayagam, P.T., Pinney, J.H., Rannigan, L.G., Gillmore, J.D. & Hawkins, P.N. (2010) ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK. Amyloid-Journal of Protein Folding Disorders, 17(Suppl. 1), 141.
68. Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., Peccatori, J., Catalano, L., Carella, A.M., Cafro, A.M., Siniscalchi, A., Crippa, C., Petrucci, M.T., Yehuda, D.B., Beggiato, E., Di Toritto, T.C., Boccadoro, M., Nagler, A. & Palumbo, A. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 119, 933-939.
69. Lebovic, D., Hoffman, J., Levine, B.M., Hassoun, H., Landau, H., Goldsmith, Y., Maurer, M.S., Steingart, R.M., Cohen, A.D. & Comenzo, R.L. (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British Journal of Haematology, 143, 369-373.
70. Lin, G., Dispenzieri, A., Kyle, R., Grogan, M. & Brady, P.A. (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. Journal of Cardiovascular Electrophysiology, 24, 793-798.
71. Madan, S., Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Dingli, D., Rajkumar, S.V., Hogan, W.J., Leung, N., Grogan, M. & Gertz, M.A. (2012) High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood, 119, 1117-1122.
72. Martinez-Vea, A., Garcia, C., Carreras, M., Revert, L. & Oliver, J.A. (1990) End-stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis. American Journal of Nephrology, 10, 283-289.
73. Mehta, J., Dispenzieri, A. & Gertz, M.A. (2010) High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biology of Blood and Marrow Transplantation, 16, 138-140.
74. Mhaskar, R., Kumar, A., Behera, M., Kharfan-Dabaja, M.A. & Djulbegovic, B. (2009) Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biology of Blood and Marrow Transplantation, 15, 893-902.
75. Mikhael, J.R., Schuster, S.R., Jimenez-Zepeda, V.H., Bello, N., Spong, J., Reeder, C.B., Stewart, A.K., Bergsagel, P.L. & Fonseca, R. (2012) Cyclophosphamide-bortezomib-dexamethasone (cybord) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 119, 4391-4394.
76. Mollee, P.N., Wechalekar, A.D., Pereira, D.L., Franke, N., Reece, D., Chen, C. & Stewart, A.K. (2004) Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplantation, 33, 271-277.
77. Mollee, P., Tiley, C., Cunningham, I., Moore, J., Prince, H.M., Cannell, P., Gibbons, S., Tate, J., Paul, S., Mar Fan, H. & Gill, D.S. (2012) A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157, 766-769.
78. Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A., Caillot, D., Hermine, O., Attal, M., Hamidou, M., Nedellec, G., Ferrant, A., Audhuy, B., Bataille, R., Milpied, N. & Harousseau, J.L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766-769.
79. Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X., Bridoux, F., Salles, G., Leblond, V., Roussel, M., Alakl, M., Hermine, O., Planche, L., Harousseau, J.L. & Fermand, J.P. (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 116, 4777-4782.
80. Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N. & Laffan, M. (2000) Bleeding symptoms and coagulation abnormalities in 337 patients with AL amyloidosis. British Journal of Haematology, 110, 454-460.
81. Palladini, G., Anesi, E., Perfetti, V., Obici, L., Invernizzi, R., Balduini, C., Ascari, E. & Merlini, G. (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 113, 1044-1046.
82. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936-2938.
83. Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B. & Merlini, G. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 2949-2951.
84. Palladini, G., Russo, P., Nuvolone, M., Lavatelli, F., Perfetti, V., Obici, L. & Merlini, G. (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 110, 787-788.
85. Palladini, G., Russo, P., Lavatelli, F., Nuvolone, M., Albertini, R., Bosoni, T., Perfetti, V., Obici, L., Perlini, S., Moratti, R. & Merlini, G. (2009) Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 88, 347-350.
86. Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., Schonland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. Journal of Clinical Oncology, 30, 4541-4549.
87. Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., Caccialanza, R., Perlini, S. & Merlini, G. (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 99, 743-750.
88. Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R.D., Kemp, J.A., Yamamura, K., Suzuki, M., Taylor, G.W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S.P. & Hawkins, P.N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417, 254-259.
89. Perfetti, V., Siena, S., Palladini, G., Bregni, M., Di Nicola, M., Obici, L., Magni, M., Brunetti, L., Gianni, A.M. & Merlini, G. (2006) Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 91, 1635-1643.
90. Petre, S., Shah, I.A. & Gilani, N. (2008) Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy. Alimentary Pharmacology & Therapeutics, 27, 1006-1016.
91. Pinney, J.H., Lachmann, H.J., Bansi, L., Wechalekar, A.D., Gilbertson, J.A., Rowczenio, D., Sattianayagam, P.T., Gibbs, S.D.J., Orlandi, E., Wassef, N.L., Bradwell, A.R., Hawkins, P.N. & Gillmore, J.D. (2011) Outcome in renal AL amyloidosis following chemotherapy. Journal of Clinical Oncology, 29, 674-781.
92. Poullos, P.D. & Stollman, N. (2003) Gastrointestinal amyloidosis: approach to treatment. Current Treatment Options in Gastroenterology, 6, 17-25.
93. Reece, D.E., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J.P., Vescio, R.A., Liu, X., Elsayed, Y.A., Cakana, A. & Comenzo, R.L. (2009) Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 114, 1489-1497.
94. Rubinow, A., Skinner, M. & Cohen, A.S. (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation, 63, 1285-1288.
95. Saba, N., Sutton, D., Ross, H., Siu, S., Crump, R., Keating, A. & Stewart, A. (1999) High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplantation, 24, 853-855.
96. Sanchorawala, V., Wright, D.G., Seldin, D.C., Dember, L.M., Finn, K., Falk, R.H., Berk, J., Quillen, K. & Skinner, M. (2001) An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 28, 637-642.
97. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Berk, J.L., Dember, L.M., Finn, K.T. & Skinner, M. (2002) Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 117, 886-889.
98. Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. & Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381-388.
99. Sanchorawala, V., Seldin, D.C., Magnani, B., Skinner, M. & Wright, D.G. (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 36, 597-600.
100. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. & Seldin, D.C. (2007a) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492-496.
101. Sanchorawala, V., Skinner, M., Quillen, K., Finn, K.T., Doros, G. & Seldin, D.C. (2007b) Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood, 110, 3561-3563.
102. Sanchorawala, V., Seldin, D.C., Berk, J.L., Sloan, J.M., Doros, G. & Skinner, M. (2010) Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 10, 469-472.
103. Sanchorawala, V., Quillen, K., Sloan, J.M., Andrea, N.T. & Seldin, D.C. (2011) Bortezomib and high dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 96, 1890-1892.
104. Sanchorawala, V., Patel, J.M., Sloan, J.M., Shelton, A.C., Zeldis, J.B. & Seldin, D.C. (2013a) Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 98, 789-792.
105. Sanchorawala, V., Hoering, A., Seldin, D.C., Finn, K.T., Fennessey, S.A., Sexton, R., Mattar, B., Safah, H.F., Holmberg, L.A., Dean, R.M., Orlowski, R.Z. & Barlogie, B. (2013b) Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplantation, 48, 1537-1542.
106. Sattianayagam, P.T., Gibbs, S.D., Pinney, J.H., Wechalekar, A.D., Lachmann, H.J., Whelan, C.J., Gilbertson, J.A., Hawkins, P.N. & Gillmore, J.D. (2010) Solid organ transplantation in AL amyloidosis. American Journal of Transplantation, 10, 2124-2131.
107. Schey, S.A., Kazmi, M., Ireland, R. & Lakhani, A. (1998) The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma. European Journal of Haematology, 61, 306-310.
108. Schonland, S.O., Perz, J.B., Hundemer, M., Hegenbart, U., Kristen, A.V., Hund, E., Dengler, T.J., Beimler, J., Zeier, M., Singer, R., Linke, R.P., Ho, A.D. & Goldschmidt, H. (2005) Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation, 80, S160-S163.
109. Schonland, S.O., Lokhorst, H., Buzyn, A., Leblond, V., Hegenbart, U., Bandini, G., Campbell, A., Carreras, E., Ferrant, A., Grommisch, L., Jacobs, P., Kroger, N., La Nasa, G., Russell, N., Zachee, P., Goldschmidt, H., Iacobelli, S., Niederwieser, D. & Gahrton, G. (2006) Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood, 107, 2578-2584.
110. Schonland, S.O., Kroger, N., Wolschke, C., Dreger, P., Ho, A.D. & Hegenbart, U. (2009) Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". Haematologica, 94, 439-441.
111. Schwartz, R.S., Cohen, J.R. & Schrier, S.L. (1979) Therapy of primary amyloidosis with melphalan and prednisone. Archives of Internal Medicine, 139, 1144-1147.
112. Seldin, D.C., Choufani, E.B., Dember, L.M., Wiesman, J.F., Berk, J.L., Falk, R.H., O'Hara, C., Fennessey, S., Finn, K.T., Wright, D.G., Skinner, M. & Sanchorawala, V. (2003) Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clinical Lymphoma, 3, 241-246.
113. Seldin, D.C., Anderson, J.J., Sanchorawala, V., Malek, K., Wright, D.G., Quillen, K., Finn, K.T., Berk, J.L., Dember, L.M., Falk, R.H. & Skinner, M. (2004) Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 104, 1888-1893.
114. Seldin, D.C., Anderson, J.J., Skinner, M., Malek, K., Wright, D.G., Quillen, K., Finn, K., Oran, B. & Sanchorawala, V. (2006) Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 108, 3945-3947.
115. Sezer, O., Schmid, P., Shweigert, M., Heider, U., Eucker, J., Harder, H., Sinha, P., Radtke, H. & Possinger, K. (1999) Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplantation, 23, 967-969.
116. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L.A. & Cohen, A.S. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. American Journal of Medicine, 100, 290-298.
117. Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O'Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. & Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of internal medicine, 140, 85-93.
118. Varr, B.C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R.A., Arai, S., Schrier, S.L. & Witteles, R.M. (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm, 11, 158-162.
119. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., Whelan, C.J., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. & Wechalekar, A.D. (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119, 4387-4390.
120. Vesole, D.H., Perez, W.S., Akasheh, M., Boudreau, C., Reece, D.E. & Bredeson, C.N. (2006) High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clinic Proceedings, 81, 880-888.
121. Wechalekar, A.D., Goodman, H.J.B., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. Blood, 109, 457-464.
122. Wechalekar, A.D., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2008) Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica, 93, 295-298.
123. Wechalekar, A.D., Schonland, S.O., Kastritis, E., Gillmore, J.D., Dimopoulos, M.A., Lane, T., Foli, A., Foard, D., Milani, P., Rannigan, L., Hegenbart, U., Hawkins, P.N., Merlini, G. & Palladini, G. (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 121, 3420-3427.